Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | NPY4R | P50391 | 3/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | CHRND | Q07001 | 5/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26873736 | 0.85 | OPRM1 (0.48) | GRIA1OPRM1OPRD1OPRK1CHRND | |
| SCHEMBL20715782 | 0.85 | OPRM1 (0.51) | NPY1RNPY2RNPY4RNPY5ROPRM1 | |
| SCHEMBL20715847 | 0.85 | OPRM1 (0.51) | NPY1RNPY2RNPY4RNPY5ROPRM1 | |
| SCHEMBL24307421 | 0.84 | OPRM1 (0.46) | GRIA1OPRM1OPRD1OPRK1 | |
| SCHEMBL13209217 | 0.84 | IL23R (0.61) | — | |
| SCHEMBL13254722 | 0.83 | IL23R (0.54) | OPRM1OPRD1OPRK1 | |
| SCHEMBL20715581 | 0.83 | OPRM1 (0.51) | NPY1RNPY2RNPY4RNPY5ROPRM1 | |
| SCHEMBL30061253 | 0.81 | F2 (0.54) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30558191 | 0.80 | F2 (0.52) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19234767 | 0.80 | GRIA1 (0.48) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | NPY1R 21/4885NPY2R 23/4885NPY4R 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.